Laserfiche WebLink
PART ONE: TREATMENT <br />1 <br />EXHIBIT A <br />List of Opioid Remediation Uses <br />Settlement fund recipients shall choose from among abatement strategies, including but not <br />limited to those listed in this Exhibit. The programs and strategies listed in this Exhibit are not <br />exclusive, and fund recipients shall have flexibility to modify their abatement approach as <br />needed and as new uses are discovered. <br />A.TREAT OPIOID USE DISORDER (OUD) <br />Support treatment of Opioid Use Disorder (“OUD”) and any co-occurring Substance <br />Use Disorder or Mental Health (“SUD/MH”) conditions through evidence-based or <br />evidence- informed programs5 or strategies that may include, but are not limited to, those <br />that:6 <br />1.Expand availability of treatment for OUD and any co-occurring SUD/MH <br />conditions, including all forms of Medication for Opioid Use Disorder <br />(“MOUD”)7 approved by the U.S. Food and Drug Administration, including by <br />making capital expenditures to purchase, rehabilitate, or expand facilities that <br />offer treatment. <br />2.Support and reimburse evidence-based services that adhere to the American <br />Society of Addiction Medicine (“ASAM”) continuum of care for OUD and any <br />co- occurring SUD/MH conditions. <br />3.Expand telehealth to increase access to treatment for OUD and any co-occurring <br />SUD/MH conditions, including MOUD, as well as counseling, psychiatric <br />support, and other treatment and recovery support services. <br />5 Use of the terms “evidence-based,” “evidence-informed,” or “best practices” shall not limit the <br />ability of recipients to fund innovative services or those built on culturally specific needs. <br />Rather, recipients are encouraged to support culturally appropriate services and programs for <br />persons with OUD and any co-occurring SUD/MH conditions. <br />6 As used in this Exhibit, words like “expand,” “fund,” “provide” or the like shall not indicate a <br />preference for new or existing programs. <br />7 Historically, pharmacological treatment for opioid use disorder was referred to as “Medication- <br />Assisted Treatment” (“MAT”). It has recently been determined that the better term is <br />“Medication for Opioid Use Disorder” (“MOUD”). This Exhibit will use “MOUD” going <br />forward. Use of the term MOUD is not intended to and shall in no way limit abatement <br />programs or strategies now or into the future as new strategies and terminology evolve. <br />DocuSign Envelope ID: 040056EC-0D41-4D98-9C65-E01AE876A6AB